Module 3: Phytocannabinoid Pharmacology

Δ9-THC Pharmacodynamics

CBD Receptor Interactions

• Mechanism: Partial agonist at CB1 and CB2 receptors

• Canine Sensitivity: High hindbrain CB1 expression

• Toxicology: Static ataxia, hyperesthesia, incontinence

• Clinical Margin: Narrow therapeutic window in dogs

• CB1 Modulation: Negative allosteric modulator (NAM)

• Non-CB Targets: TRPV1 agonist & 5-HT1A activation

• Enzymatic Impact: Inhibits FAAH endocannabinoid clearance

• Safety Profile: High tolerability; monitor liver ALP

CBG Mechanisms & Targets

Terpenes & Entourage Effect

• Receptor Profile: α2-adrenergic agonist, TRPM8 antagonist

• CB Affinity: Weak competitive antagonist / agonist

• Therapeutic Focus: Neuroprotection & anti-inflammatory

• Clinical Utility: GI motility and ocular pressure research

• Synergy Model: Phytocannabinoid-terpenoid interaction

• β-Caryophyllene: Selective CB2 receptor full agonist

• Myrcene / Limonene: Alters BBB transport & absorption

• Extract Selection: Full-spectrum vs. purified CBD isolate

Clinical Disclaimer

This course is for veterinary continuing education. It does not constitute veterinary advice or a recommendation to prescribe any specific product. No therapeutic claims are made for unapproved products.